Amid recent financial challenges and R&D setbacks hitting Sumitomo Pharma Co., Ltd., the mid-sized Japanese firm has decided to prioritize its advanced candidates in oncology, regenerative medicine and the cell therapy area over its struggling assets in the antipsychotic space.
Sumitomo’s US subsidiary Sumitomo Pharma America, Inc. (SPMA) and Otsuka Pharmaceutical Co. Ltd. announced on 18 March a revision...